Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD
February 21 2014 - 12:34AM
Galapagos NV (Euronext: GLPG) announced today that the
Company will present posters on GLPG0634 and GLPG0974 at the
European Crohn's and Colitis Organisation annual meeting, taking
place from 20 to 22 February 2014 in Copenhagen, Denmark.
The full abstracts can be accessed through the
ECCO website
.
GLPG0634, The First Selective JAK1 Inhibitor, Shows Strong
Activity In The Mouse DSS-Colitis Model Abstract number: A-1737
Poster number: P072
GLPG0634 is an orally-available, novel JAK
inhibitor with selectivity for JAK1, developed by Galapagos.
JAKs are critical components of signalling mechanisms
utilized by a number of cytokines and growth factors, including
those that are elevated in Crohn's patients. The strong
efficacy of GLPG0634 in the pre-clinical mouse DSS-induced colitis
model will be presented during a poster session on Friday, February
21, 2014, from 12:20-13:30. The poster is available online at
www.glpg.com.
The FFA2 antagonist GLPG0974: opportunity to
treat neutrophil-driven inflammation Abstract Number: A-1557 Poster
number: DOP070
FFA2 (free fatty acid receptor 2) has been shown
to play a role in neutrophil migration. Over-activity of
neutrophils is a cause of tissue damage in illnesses such as
inflammatory bowel disease. The favorable Phase 1
pharmacokinetic, pharmacodynamic, and safety data with GLPG0974
will be presented on Friday, February 21, 2014, from 12:25-13:25 in
DOP Session Room 8 in Hall B. The presentation is available
online at www.glpg.com.
About candidate drug GLPG0634
GLPG0634 differentiates from other JAK inhibitors in development by
specifically targeting JAK1, a strategy which could result in a
better efficacy and safety profile. GLPG0634 is a fully
proprietary program. Upon successful completion of the Phase
2b studies in RA, AbbVie will license the program and will assume
sole responsibility for Phase 3 clinical development and global
manufacturing. Furthermore, Galapagos recently announced the
start of a Phase 2 study with GLPG0634 in Crohn's Disease.
About candidate drug GLPG0974
GLPG0974 is an orally available small molecule that reduces
migration of neutrophils, one of the critical cell types in
inflammatory processes, by potent inhibition of FFA2 (also known as
GPR43). Over-activity of neutrophils is a cause of tissue
damage in illnesses such as inflammatory bowel disease. A
reduction of neutrophil activation and migration by inhibition of
FFA2 may provide for a novel anti-inflammatory treatment approach.
By inhibiting FFA2, GLPG0974 prevents free fatty acid-induced
activation and migration of neutrophils towards an inflammatory
site, such as in the gut of patients with inflammatory bowel
disease. GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically.
About ECCO The European Crohn's
and Colitis Organisation (ECCO), founded in 2001, is now the
largest forum for specialists in IBD in the world. It is a
non-profit association, which successfully expanded from an
organisation comprising 14 Country Members to an association
assembling 33 member states of the Council of Europe and
facilitating collaborations beyond Europe's borders. ECCO's
mission is to improve the care of patients with IBD in all its
aspects through international guidelines for practice, education,
research and collaboration in the area of IBD. More info at:
https://www.ecco-ibd.eu/
About Galapagos Galapagos
(Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising of six Phase 2
studies (three led by GSK), one Phase 1 study, six pre-clinical,
and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will
be responsible for further development and commercialization of
GLPG0634 after Phase 2B. GLPG0634 is an orally-available,
selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in
Phase 2B studies in RA and in Phase 2 in Crohn's disease.
Galapagos has another selective JAK1 inhibitor in Phase 2 in
ulcerative colitis, psoriasis, and lupus, GSK2586184 (formerly
GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0974
is the first inhibitor of FFA2 to be evaluated clinically for the
treatment of IBD; this program is currently in a Proof-of-Concept
Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and has completed Phase 1.
AbbVie and Galapagos signed an agreement in CF where they
work collaboratively to develop and commercialize oral drugs that
address two mutations in the CFTR gene, the G551D and F508del
mutation. Potentiator GLPG1837 is at the pre-clinical
candidate stage. The Galapagos Group, including
fee-for-service companies BioFocus, Argenta and Fidelta, has around
800 employees and operates facilities in five countries, with
global headquarters in Mechelen, Belgium. Further information
at: www.glpg.com
Contact
Elizabeth Goodwin, Head of Corporate
Communications & Investor Relations Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking
statements, including, without limitation, statements containing
the words "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," and
"continues," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
Galapagos to present GLPG0634 and GLPG0974 at ECCO
http://hugin.info/133350/R/1763510/597669.pdf
HUG#1763510
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jul 2023 to Jul 2024